Preoperative Concurrent Chemotherapy and Intensity Modulated Radiotherapy (IMRT) in Locally Advanced Rectal Cancer

NCT ID: NCT01340508

Last Updated: 2011-04-22

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: PHASE2
• Total Enrollment: 63 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-01-31
• Study Completion Date: 2013-01-31

Brief Summary

The hypothesis of this study is that dose escalated intensity modulated radiotherapy (IMRT) to a dose of 55Gy in 25# to primary rectal tumor concurrent with oral capecitabine results in an improved pathological response rate from 8% (German trial) to 25%.

Detailed Description

This study aims to look at whether radiation dose escalation with intensity modulated radiotherapy can increase the rates of pathological complete response in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy

Conditions

Rectal Cancers.

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Intensity modulated Radiotherapy

Intensity modulated radiotherapy, dose escalation, rectal cancer, volumetric modulated arc therapy

Group Type: EXPERIMENTAL

Intensity Modulated Radiotherapy

Intervention Type: RADIATION

Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions

Interventions

Intensity Modulated Radiotherapy

Intensity modulated radiotherapy to a dose of 55Gy in 25 fractions

Intervention Type: RADIATION

Other Intervention Names

Intensity modulated radiotherapy. Dose escalation.

Eligibility Criteria

Inclusion Criteria

• Pathologically proven diagnosis of adenocarcinoma of the rectum
• Clinically determined to be stage T3 or T4,N0-N2, and M0 -staged by MRI or transrectal ultrasound of the rectum
• Patients who are medically operable and who have resectable adenocarcinoma of the rectum at least <15cm from the anal verge
• Adequate liver/renal and haematological function.
• Eastern Cooperative Oncology Group (ECOG) performance 0-2
• Age ≥ 18 years
• Full blood count obtained within 2 weeks prior to registration on study, with adequate bone marrow function defined as follows:

• Absolute neutrophil count (ANC) ≥ 1,800 cells/mm3
• Platelets ≥ 100,000 cells/mm3
• Haemoglobin ≥ 8.0 g/dl
• Serum creatinine within normal institutional limits or creatinine clearance ≥ 50 ml/min
• Bilirubin within normal institutional limits
• AST and ALT < 2.5 x the IULN
• Patient must sign study specific informed consent prior to study entry

Exclusion Criteria

Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years

• Prior systemic chemotherapy for colorectal cancer; note that prior chemotherapy for a different cancer is allowable.
• Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields
• Severe, active comorbidity, defined as follows:

• Unstable angina and/or congestive heart failure requiring hospitalization within the last 12 months
• Transmural myocardial infarction within the last 6 months
• Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects
• Acquired immune deficiency syndrome (AIDS) based upon current CDC definition; note, however, that HIV testing is not required for entry into this protocol.
• Evidence of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding informed consent, or interfering with compliance of oral drug intake.
• Known, existing uncontrolled coagulopathy. Patients on therapeutic anticoagulation may be enrolled provided that they have been clinically stable on anti-coagulation for at least 2 weeks.
• Major surgery within 28 days of study enrollment (other than diverting colostomy)
• Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; this exclusion is necessary because the treatment involved in this study may be significantly teratogenic
• Prior allergic reaction to capecitabine
• Any evidence of distant metastases (M1)
• A synchronous primary colon carcinoma
• Extension of malignant disease into the anal canal
• Lack of physical integrity of the gastrointestinal tract (i.e., severe Crohn's disease that results in
• malabsorption; significant bowel resection that would make one concerned about the absorption of capecitabine) or malabsorption syndrome that would preclude feasibility of oral chemotherapy (capecitabine)
• Participation in any investigational drug study within 28 days of study enrollment

• Minimum Eligible Age: 21 Years
• Maximum Eligible Age: 90 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Tan Tock Seng Hospital

OTHER

Sponsor Role: collaborator

National University Hospital, Singapore

OTHER

Sponsor Role: lead

Responsible Party

National University Hospital

Principal Investigators

Jeremy Tey, FRANZCR

Role: PRINCIPAL_INVESTIGATOR

National University Hospital, Singapore

Locations

National University Hospital

Singapore, Singapore, Singapore

Site Status: RECRUITING

Countries

Singapore

Facility Contacts

Jeremy Tey, FRANZCR

Role: primary

Jeremy_tey@nuhs.edu.sg

+ 6567724869

References

Ryan R, Gibbons D, Hyland JM, Treanor D, White A, Mulcahy HE, O'Donoghue DP, Moriarty M, Fennelly D, Sheahan K. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005 Aug;47(2):141-6. doi: 10.1111/j.1365-2559.2005.02176.x.

Reference Type: BACKGROUND

PMID: 16045774 (View on PubMed)

Other Identifiers

B/09/377

Identifier Type: -

Identifier Source: org_study_id